This study aimed to evaluate the safety and pharmacokinetic characteristics of DW5124 and DW5124-R, and the effect of food on DW5124, in healthy adult volunteers.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
55
Chungbuk National University Hospital
Cheongju-si, South Korea
Peak Plasma Concentration (Cmax)
Pharmacokinetics of DW5124-fed and DW5124-fasting, Pharmacokinetics of DW5124-fed and DW5124-R-fed
Time frame: up to 72 hour
Area under the plasma concentration versus time curve (AUC)
Pharmacokinetics of DW5124-fed and DW5124-fasting, Pharmacokinetics of DW5124-fed and DW5124-R-fed
Time frame: up to 72 hour
Time to maximum plasma concentration (Tmax)
Pharmacokinetics of DW5124-fed, DW5124-fasting, DW5124-R-fed
Time frame: up to 72 hour
Terminal half life (t1/2)
Pharmacokinetics of DW5124-fed, DW5124-fasting, DW5124-R-fed
Time frame: up to 72 hour
Apparent clearance (CL/F)
Pharmacokinetics of DW5124-fed, DW5124-fasting, DW5124-R-fed
Time frame: up to 72 hour
Apparent volume of distribution (Vd/F)
Pharmacokinetics of DW5124-fed, DW5124-fasting, DW5124-R-fed
Time frame: up to 72 hour
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.